Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Biomarkers for Meningioma
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Biomarkers for Meningioma

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 24705

Special Issue Editors

Prof. Dr. Oliver Clemens Hanemann

E-Mail Website
Guest Editor
Peninsula Medical School, University of Plymouth, Plymouth, UK
Interests: meningioma; biomarker; Neurofibromatosis 2; schwannoma; targeted therapy
Dr. Houtan Noushmehr

E-Mail Website
Guest Editor
1. Department of Genetics, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil
2. Department of Neurosurgery, Brain Tumor Center, Henry Ford Health System, Detroit, MI, USA
Interests: epigenetics; biomarker; glioma; meningioma; master regulator

Special Issue Information

Dear Colleagues,

Meningiomas are the most common primary brain tumours. The current histological classification of meningioma is based on the 2016 WHO recommendations. According to the WHO criteria, meningiomas are classified into 15 histopathological subtypes, which indicate the heterogeneous nature of these tumors. Reflecting their potential clinical course, these subtypes are grouped under WHO grades I through III (benign, intermediate, and malignant subtypes).The 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) reformulated the concept of how CNS tumor diagnoses should be structured in the molecular era by adding molecular parameters in addition to histology to define many tumor entities or types (Louis et al. 2016). The change was built on the expansion of knowledge of molecular alterations in tumors and on the growing evidence that integrated histological-molecular features may be superior to a purely histological classification.

In addition, the decision to operate/treat meningiomas is currently based on patients developing new symptoms or showing growth in serial MRI. No blood biomarkers exist currently.

This Special Issue will focus on menigioma biomarkers for prognostic and diagnostic applications and potential relevance for treatment.

Prof. Dr. Oliver Clemens Hanemann
Dr. Houtan Noushmehr
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • meningioma
  • biomarkers
  • tumorigenesis
  • liquid biopsy
  • tissue biomarker

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1374 KiB  
Article
Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas
by Agbolahan A. Sofela, David A. Hilton, Sylwia Ammoun, Daniele Baiz, Claire L. Adams, Emanuela Ercolano, Michael D. Jenkinson, Kathreena M. Kurian, Mario Teo, Peter C. Whitfield, Felix Sahm and C. Oliver Hanemann
Int. J. Mol. Sci. 2021, 22(2), 560; https://doi.org/10.3390/ijms22020560 - 8 Jan 2021
Cited by 12 | Viewed by 4786
Abstract
There is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. There is currently no consensus on the optimum management of WHO grade II meningiomas. In this study, we identified the calcium [...] Read more.
There is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. There is currently no consensus on the optimum management of WHO grade II meningiomas. In this study, we identified the calcium binding extracellular matrix glycoprotein, Fibulin-2, via mass-spectrometry-based proteomics, assessed its expression in grade I and II meningiomas and explored its potential as a grade II biomarker. A total of 87 grade I and 91 grade II different meningioma cells, tissue and plasma samples were used for the various experimental techniques employed to assess Fibulin-2 expression. The tumours were reviewed and classified according to the 2016 edition of the Classification of the Tumours of the central nervous system (CNS). Mass spectrometry proteomic analysis identified Fibulin-2 as a differentially expressed protein between grade I and II meningioma cell cultures. Fibulin-2 levels were further evaluated in meningioma cells using Western blotting and Real-time Quantitative Polymerase Chain Reaction (RT-qPCR); in meningioma tissues via immunohistochemistry and RT-qPCR; and in plasma via Enzyme-Linked Immunosorbent Assay (ELISA). Proteomic analyses (p < 0.05), Western blotting (p < 0.05) and RT-qPCR (p < 0.01) confirmed significantly higher Fibulin-2 (FBLN2) expression levels in grade II meningiomas compared to grade I. Fibulin-2 blood plasma levels were also significantly higher in grade II meningioma patients compared to grade I patients. This study suggests that elevated Fibulin-2 might be a novel grade II meningioma biomarker, when differentiating them from the grade I tumours. The trend of Fibulin-2 expression observed in plasma may serve as a useful non-invasive biomarker. Full article
(This article belongs to the Special Issue Biomarkers for Meningioma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 487 KiB  
Review
Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma
by Rafael Roesler, Barbara Kunzler Souza and Gustavo R. Isolan
Int. J. Mol. Sci. 2021, 22(21), 11352; https://doi.org/10.3390/ijms222111352 - 21 Oct 2021
Cited by 2 | Viewed by 2377
Abstract
Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past [...] Read more.
Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years, providing a rational basis for the identification of biomarkers and therapeutic targets. The role of receptor tyrosine kinases (RTKs) as oncogenes, including those of the ErbB family of receptors, has been well established in several cancer types. Here, we review histological, molecular, and clinical evidence suggesting that RTKs, including the epidermal growth factor receptor (EGFR, ErbB1), as well as other members of the ErbB family, may be useful as biomarkers and therapeutic targets in MGM. Full article
(This article belongs to the Special Issue Biomarkers for Meningioma)
►▼ Show Figures

Figure 1

13 pages, 1540 KiB  
Review
Genomic Biomarkers of Meningioma: A Focused Review
by Jacob A. Pawloski, Hassan A. Fadel, Yi-Wen Huang and Ian Y. Lee
Int. J. Mol. Sci. 2021, 22(19), 10222; https://doi.org/10.3390/ijms221910222 - 23 Sep 2021
Cited by 13 | Viewed by 4090
Abstract
Meningiomas represent a phenotypically and genetically diverse group of tumors which often behave in ways that are not simply explained by their pathologic grade. The genetic landscape of meningiomas has become a target of investigation as tumor genomics have been found to impact [...] Read more.
Meningiomas represent a phenotypically and genetically diverse group of tumors which often behave in ways that are not simply explained by their pathologic grade. The genetic landscape of meningiomas has become a target of investigation as tumor genomics have been found to impact tumor location, recurrence risk, and malignant potential. Additionally, targeted therapies are being developed that in the future may provide patients with personalized chemotherapy based on the genetic aberrations within their tumor. This review focuses on the most common genetic mutations found in meningiomas of all grades, with an emphasis on the impact on tumor location and clinically relevant tumor characteristics. NF-2 and the non-NF-2 family of genetic mutations are summarized in the context of low-grade and high-grade tumors, followed by a comprehensive discussion regarding the genetic and embryologic basis for meningioma location and phenotypic heterogeneity. Finally, targeted therapies based on tumor genomics currently in use and under investigation are reviewed and future avenues for research are suggested. The field of meningioma genomics has broad implications on the way meningiomas will be treated in the future, and is gradually shifting the way clinicians approach this diverse group of tumors. Full article
(This article belongs to the Special Issue Biomarkers for Meningioma)
►▼ Show Figures

Figure 1

12 pages, 1629 KiB  
Review
Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis
by Suha Bachir, Sanjit Shah, Scott Shapiro, Abigail Koehler, Abdelkader Mahammedi, Ravi N. Samy, Mario Zuccarello, Elizabeth Schorry and Soma Sengupta
Int. J. Mol. Sci. 2021, 22(2), 690; https://doi.org/10.3390/ijms22020690 - 12 Jan 2021
Cited by 51 | Viewed by 12539
Abstract
Patients diagnosed with neurofibromatosis type 2 (NF2) are extremely likely to develop meningiomas, in addition to vestibular schwannomas. Meningiomas are a common primary brain tumor; many NF2 patients suffer from multiple meningiomas. In NF2, patients have mutations in the NF2 gene, specifically with [...] Read more.
Patients diagnosed with neurofibromatosis type 2 (NF2) are extremely likely to develop meningiomas, in addition to vestibular schwannomas. Meningiomas are a common primary brain tumor; many NF2 patients suffer from multiple meningiomas. In NF2, patients have mutations in the NF2 gene, specifically with loss of function in a tumor-suppressor protein that has a number of synonymous names, including: Merlin, Neurofibromin 2, and schwannomin. Merlin is a 70 kDa protein that has 10 different isoforms. The Hippo Tumor Suppressor pathway is regulated upstream by Merlin. This pathway is critical in regulating cell proliferation and apoptosis, characteristics that are important for tumor progression. Mutations of the NF2 gene are strongly associated with NF2 diagnosis, leading to benign proliferative conditions such as vestibular schwannomas and meningiomas. Unfortunately, even though these tumors are benign, they are associated with significant morbidity and the potential for early mortality. In this review, we aim to encompass meningiomas and vestibular schwannomas as they pertain to NF2 by assessing molecular genetics, common tumor types, and tumor pathogenesis. Full article
(This article belongs to the Special Issue Biomarkers for Meningioma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop